We hypothesize that this protein is likely an as yet unidentified target kinase of ibrutinib distinct from BTK that may be the relevant for the effects of ibrutinib on BTK-negative MM and MCL cells alone or in combination with proteasome inhibition. Here, BTK is linked to mantle cell lymphoma.